Vendors launch trade group for increasing regulatory approvals for EPA- and DHA-based products, developing education strategies and consumer awareness and implementing quality standards that will protect omega-3 EPA/DHA brands at Natural Products Expo East in Baltimore Oct. 4-7. The Global Organization for EPA & DHA Omega-3 (GOED Omega-3) includes processors, refiners, manufacturers, distributors, marketers and retailers as well as healthcare professionals, educators and researchers. GOED Omega-3 will take on a broader mandate than CRN's now-dissolved Omega-3 Working Group, but will also build on its accomplishments, including product-quality focus and industry acceptance of the voluntary Omega-3 monograph, the group says. GOED Omega-3's start-up committee includes Robert Orr, president and CEO of Ocean Nutrition Canada; Philip Fass, vice president of sales/marketing at Martek Biosciences; Bjorn Rene, vice president of sales at Napro Pharma; and Ian Newton, president of Ceres Consulting...
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
With a 25-27 June meeting looming, HHS Secretary Robert F. Kennedy Jr. can fill all 17 spots on the CDC's Advisory Committee on Immunization Practices with people he says will "exercise independent judgment."
The group had been laid off as part of the 1 April reduction-in-force, which lead to missed guidance publication deadlines.
Clinical trial sponsors in the rare disease space face “big safety demands” from regulators, which can be challenging for those with limited resources. A CRO founder makes the case for “embedding automation” into the clinical trial process to keep pace with regulatory requirements.
